Results 181 to 190 of about 523,710 (310)

Where, How, and How Much? A Multicenter Cohort Study of the Relationship Across Lupus Decision‐Aid Modality, Place of Administration, Interruption and Viewing Completeness, and Patient‐Reported Outcomes

Arthritis Care &Research, EarlyView.
Objective We assessed whether shared decision‐making (SDM) and patient acceptability, feasibility, and overall satisfaction with a computerized patient decision aid (PtDA) for patients with systemic lupus erythematosus (SLE) differs by PtDA setting, modality, and the viewing experience. Methods Patients with SLE were invited to view a self‐administered
Jasvinder A. Singh, Mark Beasley, Larry R. Hearld, for the Implementing Decision‐Aid for Lupus in Clinics (IDEAL) Consortium, Winn Chatham, Jasvinder Singh, Sonali Narain, Narender Annapureddy, Diane Kamen, Kimberly Trotter, Vikas Majithia, Cathy Ching, Zineb Aouhab, Swamy Venturupalli, Rosalind Ramsey‐Goldman, Alfred Kim, Maureen McMahon, Sam Lim, Kalpana Bhairavarasu, Alexa Meara, Kenneth Kalunian   +20 more
wiley   +1 more source

The impact of vanishing white matter on unaffected family members. [PDF]

Orphanet J Rare Dis
van Voorst RJ, Schoenmakers DH, van Beelen I, Gavazzi F, Chapleau A, Vanderver A, Bernard G, Krägeloh-Mann I, van der Knaap MS.   +8 more
europepmc   +1 more source

Treating lupus nephritis patients to lupus low disease activity reduces renal relapse and preserves long‐term kidney function

Arthritis Care &Research, Accepted Article.
Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE) but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment, and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung, Desmond YH Yap, KL Lee, Philip H Li, Iris YK Tang, Chak Sing Lau, Shirley CW Chan   +6 more
wiley   +1 more source

White matter hyperintensities precede other biomarkers in GRN frontotemporal dementia. [PDF]

Alzheimers Dement
Soltaninejad M, Dadar M, Collins DL, Rajabli R, Venkatraghavan V, Bouzigues A, Russell LL, Foster PH, Ferry-Bolder E, van Swieten JC, Jiskoot LC, Seelaar H, Sanchez-Valle R, Laforce R, Graff C, Galimberti D, Vandenberghe R, de Mendonça A, Tiraboschi P, Santana I, Gerhard A, Levin J, Nacmias B, Otto M, Bertoux M, Lebouvier T, Butler CR, Ber IL, Finger E, Tartaglia MC, Masellis M, Rowe JB, Synofzik M, Moreno F, Borroni B, Rohrer JD, Iturria-Medina Y, Ducharme S, GENFI Consortium.   +38 more
europepmc   +1 more source

Brain specific proteins in the cerebrospinal fluid: markers of damage to the periventricular white matter and prognosis after intraventricular haemorrhage [PDF]

, 1999
Mats Blennow, Lars Rosengren, Andrew Whitelaw   +2 more
openalex   +1 more source

Global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis burden, 1990–2021

Arthritis Care &Research, Accepted Article.
Objective This study examined the global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis (OA) burden from 1990 to 2021. Methods Age‐standardized years lived with disability rate for site‐specific OA across 204 countries/territories were obtained from the Global Burden of Diseases Study (GBD) 2021.
Haowei Chen, Lei Si, David J Hunter, Lei Zhang, Zhe‐Sheng Chen, Xiaomeng Wang, Vicky Duong, Zhounan Zhou, Peihua Cao, Han Cen, Su'an Tang, Tianyu Chen, Houjun Xue, Zhaohua Zhu, Changhai Ding   +14 more
wiley   +1 more source

Apathy progression is associated with brain atrophy and white matter damage in Parkinson's disease. [PDF]

Brain Commun
Moqadam R, Azizi H, Brzezinski-Rittner A, Ronat LA, Raeesi S, Hanganu A, Zeighami Y, Dadar M.   +7 more
europepmc   +1 more source

Impaired cognitive function in hypertensive patients with asymptomatic cerebral white matter lesions [PDF]

, 1999
Cristina Sierra
openalex   +1 more source

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Impact of regional white matter hyperintensity patterns on cognitive trajectories in NACC. [PDF]

Alzheimers Dement
Rotblatt LJ, Edwards L, Erani F, Terao CM, Bangen KJ, Thomas KR.   +5 more
europepmc   +1 more source